A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jose Iglesias, MD
Consultant Chief Medical Officer for HiberCell, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Sarah Cannon Research Institute /tennessee Oncology
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- the University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Feb 2022
- Primary completion
- 9 Feb 2024
- Completion
- 1 Mar 2024
- Last update posted
- 8 Mar 2024
- Registered enrollment
- 35
- Registry id
- NCT05121948
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.